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COVID-19Although several pharmacological agents are under investigation to be repurposed as therapeutic against
COVID-19, not much success has been achieved yet. So, the search for an effective and active option for
the treatment of COVID-19 is still a big challenge. The Spike protein (S), RNA-dependent RNA polymerase
(RdRp), and Main protease (Mpro) are considered to be the primary therapeutic drug target for COVID-19.
In this study we have screened the drugbank compound library against the Main Protease. But our search
was not limited to just Mpro. Like other viruses, SARS-CoV-2, have also acquired unique mutations. These
mutations within the active site of these target proteins may be an important factor hindering effective
drug candidate development. In the present study we identified important active site mutations within
the SARS-CoV-2 Mpro (Y54C, N142S, T190I and A191V). Further the drugbank database was computa-
tionally screened against Mpro and the selected mutants. Finally, we came up with the common mole-
cules effective against the wild type (WT) and all the selected Mpro. The study found Imiglitazar, was
found to be the most active compound against the wild type of Mpro. While PF-03715455 (Y54C),
Salvianolic acid A (N142S and T190I), and Montelukast (A191V) were found to be most active against
the other selected mutants. It was also found that some other compounds such as Acteoside, 4-Amino-
N- {4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pentyl}-Benzamide,
PF-00610355, 4-Amino-N-4-[2-(2,6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-
Pentyl}-Benzamide and Atorvastatin were showing high efficacy against the WT as well as other selected
mutants. We believe that these molecules will provide a better and effective option for the treatment of
COVID-19 clinical manifestations.
 2021 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction avirus family, and is responsible for the highly contagious andFirst reported from Wuhan, China, Severe acute respiratory
syndrome-Coronavirus-2 (SARS-CoV-2) is a newmember of Coron-infectious viral disease (COVID-19) (Zhu et al., 2020). Since the out-
break, World Health Organization (WHO) reported 74 million
COVID-19 cases and 1.65 million COVID-19 cases-associated
deaths worldwide (until mid-January 2020). Coronaviruses, (en-
veloped viruses belonging to coronaviridae family) are found in
mammalian and avian species (Zhu et al., 2020). The coronaviruses
are classified into different genera (a, b, c and d) (Kaul 2020). The
causal agent of the current pandemic SARS-CoV-2 belongs to gen-
era beta coronaviruses and is diligently linked to MERS-CoV and
SARS-CoV, sharing > 79% of genomic sequence similarity. Owing
to the human-to-human transmission of the virus, the re-
emergence of SARS (2002–03 epidemic) and other coronaviruses
may prove to be a discrete prospect and therefore there is an
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proteins.
Amongst all the studied coronaviral drug targets, the main pro-
tease (Mpro) received major attention (Ziebuhr 2004; Ullrich and
Nitsche 2020). The non-structural protein (nsp) of SARS-CoV-2,
main protease (Mpro), sharing high sequence similarity with its
SARS-CoV counterpart, and has emerged as a promising therapeu-
tic target. Mpro gained major attention particularly in 2000s dur-
ing the first SARS-CoV outbreak (Anand et al., 2003, Yang, Yang
et al. 2003). This viral protease is well validated drug target and
a number of drugs has been reported to be targeting this protease
for the treatment of various diseases like HIV, HCV etc. (Agbowuro
et al., 2018; Bafna et al., 2020; Mahdi et al., 2020). The Mpro of
SARS-CoV-2 is reported to be proteolytically cleaving the overlap-
ping pp1ab polyproteins into the functional proteins (Fig. 1). This
cleavage of ppa1ab is a critical step involved in the viral replica-
tion. Mpro cleaves the large virion polyproteins (pp1a and b) at
11 sites, resulting in the release of 16 NSPs (Prajapat et al.,
2020). Owing to the significance of viral replication cycle, Mpro
has been anticipated as a target in the development of inhibitor
against coronaviruses (Yang et al., 2003). In the last few years,
especially since the start of this pandemic, the drug repurposing
has emerged as a successful drug development alternative (Sleire
et al., 2017; Cha et al., 2018; Chen et al., 2020). This alternative
drug discovery approach has been proved very successful in the
identification of effective drug candidates against hepatitis C,
Ebola, and zika virus (Bai and Hsu 2019; Xie and Shi 2019). Though
the Mpro, is known to be highly conserved across the coronaviri-
dae family, but the mutations within this protease may pose a
challenge (Bzowka et al., 2020). The aim of this study was to iden-
tify the prominent active site mutations within Mpro and to iden-
tify Mpro inhibitory molecules using virtual screening-based drug
repurposing method. The molecules reported in this study were
found to be effective against the WT as well as the mutant Mpro.
The valuable information derived from this study will be useful
in the repurposing of compounds as a selective and effective inhi-
bitor of the SARS-CoV-2 Mpro and their mutants.Fig. 1. The life cycle of SARS-CO
31532. Material and methods
2.1. Sequence analysis and mutation identification
The sequence of protein of the SARS-COV-2 Mpro was extracted
from the NCBI database (Coordinators 2016). BLAST (Boratyn et al.,
2013) search was performed against the selected sequence and all
the mutants were selected. To delineate and analyze the mutation
across different countries, an in-house script written in Perl and
Python was used (Khan et al., 2020). Further the classification
was made on the basis of the active site mutation. A total of 4 dif-
ferent active site mutations were considered in this study (Gen-
Bank: QJD23268.1, QJC19621.1, QJA16866.1 and QIZ14843.1).
2.2. Structure modeling
The three-dimensional structures of all the mutants were gen-
erated using Modeller 9v23 (Webb and Sali 2016). The structure
of selected mutants was modelled taking Crystal structure of the
SARS-CoV-2 (COVID-19) main protease in complex with inhibitor
UAW248 as a template (pdb id: 6XBI) (Sacco et al., 2020).
2.3. Virtual screening
The library of the compounds was downloaded from the drug-
bank (Wishart et al., 2008). The structures were subjected to dock
against the WT as well as all the selected mutants. The screening
was performed using CCDC Gold. The top scoring hits from each
category was selected for further study.
2.4. Molecular dynamics
The complex of top scoring molecule against each protein was
further subjected to Molecular dynamics simulation to examine
the stability of the complex. All the molecular dynamic simulation
studies were performed using Gromacs 2020 version 4 package
(Hess et al., 2008; Pronk et al., 2013). Solvation was done in TIP3PV-2 and the role of Mpro.
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margin. System was made neutral using sodium ions. Protein-
ligand complex along with water and ions using conjugate gradient
minimization applying constant force for 50,000 steps. Isothermal
and isochoric equilibration was done using Particle Mesh Ewald
scheme for 150,000 steps. Production run was done for 50 ns using
Verlet algorithm. Analysis and plots were built using Xmgrace and
UCSF-Chimera.Fig. 3. Top selected mutant of Main Protease.3. Results
The mutants selected in this study were the active site mutation
reported from different regions. The important mutants investi-
gated in this study are shown in Fig. 2. Virtual screening of drug-
bank was performed against the SARS-CoV-2 Mpro using CCDC
GOLD. Y54C, an Mpro mutant reported in March 2020 in Malaysia
was considered in this study. Not many reports are available
regarding the occurrence of mutation. N142S was another muta-
tion considered in this study, has been reported 17 times from 5
different countries. T190I, a mutation occurring 110 times (0.03%
of the sequenced NSP5) has been reported from 15 different coun-
tries (https://www.gisaid.org/). This mutation was also considered
in this study. First reported in March 2020 from South Africa, this
mutant has recently been reported in January 2021 in US. A191V,
another active site mutation with occurrence rate of 0.30% of the
total sampled sequence was also considered in this study. A191V
has been reported so far in 34 countries. The library was also
screened against the selected Mpro mutants as well (Fig. 3). TheFig. 2. Workflow of the
3154compounds demonstrating higher binding affinities (PLP Fitness)
were selected. It was found that several compounds were showing
higher binding affinity against all the selected Mpro mutants.
Imiglitazar (Adeghate et al., 2011), a potent agonist for PPARa
and PPARc was found to be most effective against Mpro (WT)
(Table 1). This compound was binding with the PLP fitness scorevirtual screening.
Table 1
Binding details of the top selected compounds against all mutants.
Residues Involved
Hydrogen Bond Other interacting residues
Mpro (WT) Imiglitazar T26, E166 T25, L27, H41, C44, T45, S46, M49, C145, M165,
E166, L167, P168
Acteoside T26, F140, S144, H163, Q189 T25, L141, C145, M165, E166, P168, Q189, A191
PF-00610355 T25, L27, H41, S46, M49, C145, M165, E166, L167,
P168
Y54C PF-03715455 T190 H41, M49, L50, C145, M165, E166, P168, Q189,
A191




L141, G143, S144, C145, E166 T25, H41, S46, M49, L141, N142, C145, M165, E166,
D187, R188
N142S Salvianolic acid A Y54, L141, G143, S144, C145, R188, Q189,
T190, Q192




S142, G143, Q192 T25, M49, F140, L141, H163, M165, E166, L167,
H172, R188, Q189
Montelukast T26, E166, Q189 T25, H41, M49, G143, C145, M165, E166, P168,
Q189, A191
T190I Salvianolic acid A L141, H163, D187, I190, Q192 M49, L141, M165, E166, P168, Q189
Acteoside T25, H41, V42, C44, H163, Q192 T25, H41, C44, M49, N142, C145, H163, M165,
E166, P168, A191
PF-00610355 T26, H164 T26, M49, L141, N142, C145, M165, E166, R188,
Q189
A191V Montelukast T25, C44, E166 T25, H41, M49, C145, M165, E166, D187, R188,
Q189
Acteoside T25, C44, L141, S144, E166, Q189, Q192 H41, M49, N142, C145, M165, E166, P168, H172
PF-03715455 T25, N142 T25, C44, M49, L141, N142, G143
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tive against other mutants as well. Acteoside, and PF-00610355
were found to be other most active compound against WT Mpro
(PLP Fitness score: 95.4569 and 94.2133). PF-03715455, a p38 inhi-
bitor administrated for the treatment of chronic obstructive pul-
monary disease (Norman 2015) was found to be most effective
against Y54C Mpro. This compound also demonstrated high bind-
ing affinity against N142S, T190I and A191V, where it was binding
with the PLP fitness score of 94.66, 88.58 and 92.62, respectively
(Table 2). Salvianolic acid A, an antioxidant molecule extracted
from S. miltiorrhiza (Ho and Hong 2011) was found to be most
effective against the N142S and T190I. This compound known for
its chemo preventative and cardioprotective properties was found
to bind with the PLP fitness score of 97.85 and 94.2 against N142S
and T190I, respectively (Table 1 and 2). This antioxidant demon-
strated high binding efficacy against other Mpro mutants as well
(Table 2). Montelukast (Jarvis and Markham 2000), was found to
be the most active compound against A191V. This selective cys-
teinyl leukotriene receptor antagonist was found to be very effec-
tive against T190I and N142S as well (Table 2). In the present study
we focused on the top 10 scoring compounds against each mutant
and WT Mpro. Here we found that there were several compounds
showing very high efficacy against all or most of the selected
mutants (Table 2). PF-00610355 (Diderichsen et al., 2013), a mole-
cule used for the treatment of Asthma, Pulmonary Disease, and
Bronchial Diseases was found to be very effective against all the
WT and other selected mutants. Likewise, 4-Amino-N- { 4-[ 2-(2,
6-Dimethyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phe
nyl-Pentyl}-Benzamide, an anti-malarial compound known for its
inhibitory activity against Plasmepsin-2 (Asojo et al., 2002) was3155found to be very active against all the selected Mpro mutants.
The study also revealed that the active site residues playing very
prominent roles in accommodating the compounds within the
active site of Mpro and its mutants (Fig. 4). In the WT as well as
other selected mutants T25, T26, H41, C145, M165, E166, P168,
D187, R188, and Q189 were found to be very prominently involved
in accommodating the compounds within the binding pocket
(Table 1). It was also observed that the binding was dominated
by the presence of hydrogen bonds. MD studies for the top-
scoring molecule from each category in complex with their respec-
tive target (Imiglitazar-WT, PF-03715455-Y54C, Salvianolic-A-
N142S, Salvianolic-A-T190I and Montelukast-A191V) were
performed. The MD analysis provided a valuable insight on the sta-
bilities of these selected compounds in complex with their recep-
tors. Trajectory analysis and the RMSD plot analysis indicated
that the compounds namely Imiglitazar, PF-03715455 and Mon-
telukast were stable within the binding pocket of the receptor with
after the initial 20 ns run and deviations of less than 3 Å were
observed for the rest of the time-frame of the simulation
(Fig. 5A). Salvianolic-A was found to be highly stable with T190I
mutant, and a deviation of less than 2 Å was observed, while this
compound was found to be unstable with the N142S mutant
(Fig. 5A). It indicated the deviations upto 4 Å with constant varia-
tion in its bound conformation especially in the dihydroxyphenyl-
ethenyl group within the binding cavity (Fig. 5A). Hydrogen bond
analysis of the trajectory indicated that the ligands namely PF-
03715455, Montelukast and Imiglitazar were having constant
hydrogen bonds with their respective receptor proteins (Fig. 5B).
While Salvianolic-A was not forming the constant hydrogen bonds
with the N142S mutant, while for the T190I mutant the hydrogen
Table 2
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The RMSD analysis indicated that the backbone of all the selected
structures were stable throughout the simulation time period
(Fig. 5C). A slight fluctuation (~0.5 Å) was noticed in the A191V
(Fig. 5C). The RMSF analysis highlights that the residues involved
around the binding cavity were mostly stable (Fig. 5D).4. Discussion
Declared as pandemic by World Health Organization (WHO),
COVID-19 is the most threatening viral disease witnessed in the
last several decades (Ashour et al., 2020; Xu et al., 2020). Though
several vaccines are available for emergency use or in the last
phase of human trails, still there is an uncertainty (Polack et al.,
2020; Sharma et al., 2020; Singh and Upshur 2020; Knoll and
Wonodi 2021). Efforts are continuously being made towards the
characterization of pivotal molecular targets for the development
of anti-viral drugs. Of several structural and non-structural SARS-
COV-2 protein, Mpro is designated as a potential therapeutic target
for therapeutics development (Chen et al., 2020). The inhibition of
Mpro is a checkpoint preventing the viral replication and thereby
making it an important therapeutic target constitutes one of the
potential anti coronaviral strategies (Shawky et al., 2020). Recently,
a large number of studies have focused on the repurposing of old
drugs as a plausible treatment for COVID-19 (Loucera et al.,
2020; Mohapatra et al., 2020; Singh et al., 2020; Krishna et al.,31562021). The success of drug repurposing has gained large research
interest (Cusinato et al., 2020; Rubin et al., 2020). Remedesivir,
an antiviral which was originally developed to treat respiratory
syncytial virus (RSV), a hepatitis C and later investigated during
the Ebola outbreak (Pardo et al., 2020). During the COVID-19 out-
break, remedesivir becomes the first drug to receive emergency
use authorization by US-FDA (Lamb 2020). Likewise, there are sev-
eral other drugs, which have been found to show inhibitory effect
against SARS-CoV-2 (Gao et al., 2020; Watashi 2020). To continue
this effort here we have screened the drugbank against the SARS-
CoV-2 Mpro of. The novelty of this work lies in the identification
of some important active site mutations in Mpro and thereby
screening the drug databank against these mutants as well. Acteo-
side also known as Verbascoside, a phenylpropanoid glycoside
with reported antimicrobial, anti-inflammatory, antioxidant, and
antitumor activity (Shawky et al., 2020) was found to be showing
high binding affinity against the WT and all the selected mutants
(Table 2). The binding potential of this compound against Mpro
has also been discussed in previous studies as well (Shawky
et al., 2020). Salvianolic acid A, a phenolic acid extracted from sage
(Salvia officinalis) (Ma et al., 2019) was another compound demon-
strating high binding affinity against all the selected Mpro
mutants. This compound has also been previously reported to carry
inhibitory potential against Mpro (Ibrahim et al., 2020). 3,8-Dia
mino-6-phenyl-5-[6-[1-[2-[(1,2,3,4-tetrahydro-9-acridinyl)amino]
ethyl]-1H-1,2,3-triazol-4-YL]hexyl]-phenanthridinium also known
as TZ4, a widely reported inhibitor of acetylcholinesterase was also
found to be very effective against the WT and all selected Mpro
mutants (Table 2). Belonging to the quinolines, though there are
no available reports showing the linkage of this compound with
COVID-19 or its role in suppression of any viral progression, but
several molecules under this class have been reported to carrying
wide range of antiviral activity (Alexpandi et al., 2020). PF-
03715455, a p38 kinase inhibitor (Norman 2015), was another
compound screened as a potential inhibitor showing high binding
affinity against all the selected mutants (Table 2). The findings
strongly support the previous reports demonstrating the role of
p38 inhibitors in COVID-19 and related viral infections (Grimes
and Grimes 2020; Hemmat et al., 2021). Along with, there are sev-
eral p38 inhibitors under clinical trials to be used as a therapeutic
option in serious COVID-19 infection (Grimes and Grimes 2020).
PF-00610355, a b2 adrenoreceptor agonist, investigated for the
treatment of COPD and asthma (Diderichsen et al., 2013) demon-
strated notable binding efficacy against WT and all the selected
mutants. Studies have reported b2 adrenoreceptor agonist like Epi-
nephrine, formoterol, dobutamine to be carrying therapeutic
potential against COVID-19 or other viral infections (Arya et al.
2020; Bolelli et al., 2020; Derakhshan et al., 2020). There were sev-
eral other compounds reported in this study, which may be further
investigated as a potential agent to be repurposed as a therapeutic
candidate for the treatment of COVID-19. Atorvastatin was another
compound found to be demonstrating high affinity against the
selected mutants. Atorvastatin, belonging to the statin class of
medications, has been well reported to lower the severity in
COVID-19 infection (Tan et al., 2020). Currently Atorvastatin is
under Phase 2 trials for its use as Adjunctive Therapy in COVID-
19 (ClinicalTrials.gov Identifier: NCT04380402). Montelukast, an
antagonist for cysteinyl leukotriene (cysLT) receptor (Ihaku et al.,
1999) was also found to be demonstrating high binding affinity
against the selected mutants. Montelukast, widely reported to be
carrying anti-inflammatory effects has also been found to be carry-
ing antiviral activity as well (Chen et al., 2019; Park et al., 2020).
This immune modulatory has been found to be limiting the pro-
gression of COVID-19 infection. Currently this drug is under Phase
3 clinical trial to be used as COVID-19 treatment (ClinicalTrials.gov
Identifier: NCT04389411) (Fidan and Aydogdu 2020). The study
Fig. 5. Molecular dynamics results of the Imiglitazir-WT Mpro complex (Black), PF-03715455-Y54C (red), Salvianolic acidA-N142S (green), Salvianolic acidA-T190I (blue) and
Montelukast-A191V (Yellow). (A) The ligand RMSD selected compounds (B) The backbone RMSD of Mpro (WT) and mutants in complex the selected compounds (C) The
intermolecular hydrogen bond formations (D) The RMSF plot of the WT and mutant Mpro.
Fig. 4. The binding of top scoring compounds (A) Binding of Imiglitazar within the active site of Mpro (WT) (B) Binding of PF-03715455 within the active site of Mpro (Y54C)
(C) Binding of Salvianolic acid A within the active site of Mpro (N142S) (D) Mpro (T190I) (E) Binding of Montelukast within the active site of Mpro (A191V).
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and other active site residues. The role of the highlighted residues
has been well reported in previous studies (Nukoolkarn et al.,
2008; Bello et al., 2020; Shitrit et al., 2020). Overall, the findings
of this study will be helpful in shortlisting of compounds to be
repurposed as a therapeutic candidate against Mpro and its
mutants.
5. Conclusion
This study reports the list of compounds showing high binding
affinity against the SARS-CoV-2 Main protease as well as its
mutants. These compounds may open a new therapeutic option
for the repurposing of existing compounds against SARS-CoV-2.
The study highlights several compounds like Acteoside, Salvianolic
acid A, PF-03715455, Montelukast, 4-Amino-N-{4-[2-(2,6-Dime
thyl-Phenoxy)-Acetylamino]-3-Hydroxy-1-Isobutyl-5-Phenyl-Pen
tyl}-Benzamide etc. to be very effective against the WT and most of
selected Mpro mutants. We believe the use of these compounds
may offer significant anti-COVID-19 treatment option.
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